New Hypofractionation Radiation Strategies for Glioblastoma

Melissa Azoulay, Jennifer Shah, Erqi Pollom, Scott G. Soltys

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of Review: Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. Recent Findings: Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1–3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Summary: Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.

Original languageEnglish (US)
Article number58
JournalCurrent Oncology Reports
Volume19
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Glioblastoma
Radiotherapy
Radiation
Standard of Care
Survival
Chemoradiotherapy
Brain Neoplasms
Therapeutics
Quality of Life
Research Personnel

Keywords

  • Adverse radiation effect
  • Glioblastoma
  • Hypofractionation
  • Immunotherapy
  • Radiation
  • Radionecrosis
  • Radiotherapy
  • Stereotactic radiosurgery
  • Temozolomide

ASJC Scopus subject areas

  • Oncology

Cite this

New Hypofractionation Radiation Strategies for Glioblastoma. / Azoulay, Melissa; Shah, Jennifer; Pollom, Erqi; Soltys, Scott G.

In: Current Oncology Reports, Vol. 19, No. 9, 58, 01.09.2017.

Research output: Contribution to journalReview article

Azoulay, Melissa ; Shah, Jennifer ; Pollom, Erqi ; Soltys, Scott G. / New Hypofractionation Radiation Strategies for Glioblastoma. In: Current Oncology Reports. 2017 ; Vol. 19, No. 9.
@article{1201b0d145924685b07259f408955e24,
title = "New Hypofractionation Radiation Strategies for Glioblastoma",
abstract = "Purpose of Review: Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. Recent Findings: Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1–3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Summary: Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.",
keywords = "Adverse radiation effect, Glioblastoma, Hypofractionation, Immunotherapy, Radiation, Radionecrosis, Radiotherapy, Stereotactic radiosurgery, Temozolomide",
author = "Melissa Azoulay and Jennifer Shah and Erqi Pollom and Soltys, {Scott G.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s11912-017-0616-3",
language = "English (US)",
volume = "19",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "9",

}

TY - JOUR

T1 - New Hypofractionation Radiation Strategies for Glioblastoma

AU - Azoulay, Melissa

AU - Shah, Jennifer

AU - Pollom, Erqi

AU - Soltys, Scott G.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose of Review: Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. Recent Findings: Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1–3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Summary: Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.

AB - Purpose of Review: Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults, with a median survival of less than 2 years despite the standard of care treatment of 6 weeks of chemoradiotherapy. We review the data investigating hypofractionated radiotherapy (HFRT) in the treatment of newly diagnosed GBM. Recent Findings: Investigators have explored alternative radiotherapy strategies that shorten treatment duration with the goal of similar or improved survival while minimizing toxicity. HFRT over 1–3 weeks is already a standard of care for patients with advanced age or poor performance status. For young patients with good performance status, HFRT holds the promise of radiobiologically escalating the dose and potentially improving local control while maintaining quality of life. Summary: Through the use of shorter radiotherapy fractionation regimens coupled with novel systemic agents, improved outcomes for patients with GBM may be achieved.

KW - Adverse radiation effect

KW - Glioblastoma

KW - Hypofractionation

KW - Immunotherapy

KW - Radiation

KW - Radionecrosis

KW - Radiotherapy

KW - Stereotactic radiosurgery

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85025458314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025458314&partnerID=8YFLogxK

U2 - 10.1007/s11912-017-0616-3

DO - 10.1007/s11912-017-0616-3

M3 - Review article

C2 - 28735440

AN - SCOPUS:85025458314

VL - 19

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 9

M1 - 58

ER -